Inmedix CEO Andrew J Holman MD presents new CloudHRV® data at the annual meeting of the American Autonomic Society (AAS)
Inmedix CloudHRV System
Performance characteristics reveal new insights comparing updated parasympathetic indices to 1996 international standards.
NORMANDY PARK, WA, UNITED STATES, November 7, 2025 /EINPresswire.com/ -- Inmedix®, Inc. (“Inmedix”) presented today a comparison of parasympathetic clinical performance characteristics for current (1996) international standard heart rate variability (HRV) and its 2025 FDA cleared CloudHRV System. This data is of particular importance highlighting unexpected limitations in the current gold standard for 5-minute HRV clinical assessment of the autonomic nervous system (ANS).
The Inmedix CloudHRV System is the first clinic test procedure cleared by the FDA as a cloud-based HRV diagnostic calculated from a high-fidelity 5-min electrocardiogram (ECG) which also includes Baevsky indices of parasympathetic and sympathetic activity. It represents a milestone in modern HRV assessment with scalability, precision and affordability for patients and clinicians in the clinical setting.
HRV provides indirect measures of the sympathetic (fight-or-flight) and parasympathetic (rest/restorative) components of central, millisecond ANS stress management. For medical grade HRV, a precision ECG is used to identify each heartbeat and to measure the precise timing between beats. These ECG measurements of heart rate (pulse) variability over time reflect how the ANS influences cardiac rhythm during respiration. Subsequently, mathematical formulae can be applied to render HRV indices of sympathetic and parasympathetic activity.
Of note, CloudHRV is not indicated for any specific application in medicine. Its utility is determined exclusively by the clinician and the CloudHRV ECG display is contraindicated for use to monitor or diagnose cardiovascular disease.
The study, poster #79, was presented at the annual meeting of the American Autonomic Society (AAS) in Clearwater, FL November 4-8, 2025:
Holman AJ. Performance characteristics comparison between 1996 standard heart rate variability (HRV) and RM Baevsky indices in 2025 FDA-cleared CloudHRV. Clin. Auton. Res. (2025) 35:643-696.
It revealed performance limitations in the 1996 international HRV standard HF (high frequency) and RMSSD (root mean square of the standard deviation) indices of parasympathetic activity relied upon for decades in academic, clinical and commercial HRV. Interested parties should contact Inmedix for specific details. The new data is being submitted for peer review publication.
“The AAS is the premier international venue for the exchange of breakthrough diagnostics and therapeutics for disorders related to the autonomic nervous system or ANS,” said Inmedix CEO, rheumatologist and co-founder of Seattle-based Inmedix, Inc. “Precision is key to effective diagnostics in clinical care and medical grade HRV is at the cutting edge of medical discovery to improve patient care and treatment outcomes.”
“One often finds solutions in unexpected places and by having cautious willingness to challenge dogma. HRV indices were internationally standardized in 1996. This new data supports some careful reconsideration of what the gold standard should be. Additional rigorous research should clarify this question.”
About Inmedix, Inc. and its subsidiary, Inmedix UK, Ltd.
Seattle-based biotech/medtech Inmedix, Inc. and its subsidiary Inmedix UK, Ltd., are committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the impact of stress modulated within the brain by the autonomic nervous system (ANS). Its CloudHRV System is FDA cleared to provide 1996 standard time and frequency domain HRV as well as geometric domain HRV indices non-invasively in 5 minutes in the clinic setting.
NOTICE:
This Press Release contains certain forward-looking statements, including without limitation statements regarding Inmedix’s plans for preclinical studies, effectiveness of its research, product capabilities and the market’s demand for its respective products. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Inmedix’s business which could significantly affect expected results, including without limitation, progress of development, clinical testing, regulatory approval, developments in raw material, personnel costs, sales as well as legislative, fiscal, and other regulatory measures. Any forward-looking statements are qualified in their entirety by this cautionary statement, and Inmedix undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. This is not an offer to sell or an offer to purchase securities.
Andrew J Holman MD
Inmedix Inc.
+1 206-466-3349
andrew.holman@inmedix.com
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
